​

Aprea Therapeutics (APRE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

APRE Stock Rating

Aprea Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (50.00%), 2 Hold (25.00%), 2 Sell (25.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 2 2 4 Strong Sell Sell Hold Buy Strong Buy

APRE Price Target Upside V Benchmarks

TypeNameUpside
StockAprea Therapeutics-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.77$0.77$0.77
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2613---4
May, 2612---3
Apr, 2612---3
Mar, 2612---3
Feb, 2612---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 14, 2026WedbushOutperformOutperformhold
May 07, 2026OppenheimerOutperforminitialise
Mar 16, 2026H.C. WainwrightBuyBuyhold
Jan 29, 2026H.C. WainwrightBuyBuyhold
Mar 10, 2023Loop Capital MarketsBuyinitialise
Jul 08, 2022WedbushOutperforminitialise
Dec 29, 2020Morgan StanleyEqual-WeightEqual-Weighthold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.95$-2.35$-1.93---
Avg Forecast$-3.42$-2.51$-1.46$-1.48$-1.13$-0.82
High Forecast$-2.07$-2.35$-1.46$-0.73$-0.61$-0.82
Low Forecast$-4.76$-2.66$-1.46$-2.23$-1.64$-0.82
Surprise %15.50%-6.37%32.19%---

Revenue Forecast

$0 $3M $6M $9M $12M $15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$583.23K$1.50M----
Avg Forecast$689.67K$1.34M$900.00K$900.00K$1.80M$10.84M
High Forecast$850.27K$1.55M$900.00K$900.00K$1.80M$10.84M
Low Forecast$529.06K$1.12M$900.00K$900.00K$1.80M$10.84M
Surprise %-15.43%12.24%----

Net Income Forecast

$-20M $-16M $-12M $-8M $-4M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-14.29M$-12.96M$-12.60M---
Avg Forecast$-14.29M$-9.06M$-5.29M$-5.35M$-4.07M$-2.97M
High Forecast$-7.50M$-8.51M$-5.29M$-2.65M$-2.21M$-2.97M
Low Forecast$-17.23M$-9.61M$-5.29M$-8.05M$-5.93M$-2.97M
Surprise %-42.99%138.01%---

APRE Forecast FAQ

Is Aprea Therapeutics stock a buy?

Aprea Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 2 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Aprea Therapeutics is a favorable investment for most analysts.

What is Aprea Therapeutics's price target?

Aprea Therapeutics's price target, set by 8 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.77.

How does Aprea Therapeutics stock forecast compare to its benchmarks?

Aprea Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Aprea Therapeutics over the past three months?

  • June 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Aprea Therapeutics’s EPS forecast?

Aprea Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.48, marking a -23.32% decrease from the reported $-1.93 in 2025. Estimates for the following years are $-1.13 in 2027, and $-0.82 in 2028.

What is Aprea Therapeutics’s revenue forecast?

Aprea Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $900K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $1.8M, and $10.84M for 2028.

What is Aprea Therapeutics’s net income forecast?

Aprea Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-5.354M, representing a -57.51% decrease from the reported $-12.6M in 2025. Projections indicate $-4.07M in 2027, and $-2.966M in 2028.